Abstract
Until recently, the standard care for retinopathy of prematurity (ROP) was destructive treatment of the peripheral avascular retina, most often using laser therapy. Now, intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents have been included in recommendations for treatment-warranted ROP. The three anti-VEGF agents used to treat ROP are bevacizumab, ranibizumab, and aflibercept and clinical trials using, a variety of treatment strategies, have shown all three are efficacious and easy to administer. Intravitreal Bevacizumab is most used in the US, and ranibizumab has been approved for ROP use in Europe. In 2023, the FDA approved aflibercept for treatment of severe ROP. We summarize the clinical trial results and provide a side-by-side comparisons of the three drugs. Despite FDA approval of the use of aflibercept to treat ROP, there is a need for more research as the body of knowledge regarding this agent to treat ROP is limited.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Patel NA, Acaba-Berrocal LA, Hoyek S, Fan KC, Martinez-Castellanos MA, Baumal CR, et al. Practice patterns and outcomes of intravitreal anti-VEGF injection for retinopathy of prematurity. an international multicenter study. Ophthamology. 2022;129:1380–8.
Raghuveer TS, Zackula R. Strategies to prevent severe retinopathy of prematurity: a 2020 update and meta-analysis. Neoreviews. 2020;21:e249–e263. https://doi.org/10.1542/neo.21-4-e249
Hartnett ME, Stahl A. Laser versus anti-VEGF: a paradigm shift for treatment-warranted retinopathy of prematurity. Ophthalmol Ther. 2023;12:2241–52.
Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121:1684–94.
Simmons AB, Bretz CA, Wang H, Kunz E, Hajj K, Kennedy C, et al. Gene therapy knockdown of VEGFR2 in retinal endothelial cells to treat retinopathy. Angiogenesis. 2018;21:751–64.
Sauer L, Chandler M, Hartnett ME. Extending peripheral retinal vascularization in retinopathy of prematurity through regulation of VEGF signaling. Am J Ophthalmol. 2023;260:190–9. https://doi.org/10.1016/j.ajo.2023.12.008. PMID: 38141904.
Mintz-Hittner HA, Kennedy KA, Chuang ZA, for the BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N. Engl J Med. 2011;364:603–15. https://doi.org/10.1056/NEJMoa1007374
Wallace DK, Kraker RT, Freedman SF, Crouch ER, Hutchinson AK, Bhatt AR, et al. Pediatric Eye Disease Investigator Group (PEDIG). Assessment of lower doses of intravitreous bevacizumab for retinopathy of prematurity: a phase 1 dosing study. JAMA Ophthalmol. 2017;135:654–6.
Freedman SF, Hercinovic A, Wallace DK, Kraker RT, Li Z, Bhatt AR, et al. Low and very low dose bevacizumab for retinopathy of prematurity: reactivations, additional treatments, and 12-month outcomes. Ophthalmology. 2022;129:1120–8. https://doi.org/10.1016/j.ophtha.2022.05.019
Stahl A, Lepore D, Fielder A, Fleck B, Reynolds JD, Chiang MF, et al. Ranibizumab versus laser therapy for the treatment of very low birth weight infants with retinopathy of prematurity (RAINBOW): an open label randomized controlled trial. Lancet. 2019;394:1551–59.
Stahl A, Sukgen EA, Wu W-C, Lepore D, Nakanishi H, Mazela J, et al. Effect of intravitreal aflibercept vs laser photocoagulation on treatment success of retinopathy of prematurity. the FIREFLEYE randomized clinical trial. JAMA. 2022;328:348–59. https://doi.org/10.1001/jama.2022.10564
Moshfeghi DM. Effect of intravitreal aflibercept versus laser photocoagulation for retinopathy of prematurity: results from the phase 3 BUTTERFLEYE trial. Invest Ophthalmol Vis Sci. 2023;64:5126.
Stahl A, Azuma N, Wu W-C, Lepore D, Sukgen E, Nakanishi H, et al. Systemic exposure to aflibercept after intravitreal injection in premature neonates with retinopathy of prematurity: results from the FIREFLEYE randomized phase 3 study. Eye. 2024; https://doi.org/10.1038/s41433-024-02948-y
Chang E, Josan AS, Purohit R, Patel CK, Xue K. A network meta-analysis of retreatment rates following bevacizumab, ranibizumab, aflibercept, and laser for treatment of retinopathy of prematurity. Ophthalmology. 2022;129:1389–401. https://doi.org/10.1016/j.ophtha.2022.06.042
Sato T, Wada K, Arahori H, Kuno N, Imoto K, Iwahashi-Shima C, et al. Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol. 2012;153:327–33. https://doi.org/10.1016/j.ajo.2011.07.005
Wu WC, Lein R, Liao PJ, Wang NK, Chen YP, Chao AN, et al. Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity. JAMA Ophthalmol. 2015;133:391–7. https://doi.org/10.1001/jamaophthalmol.2014.5373
Zhou Y, Jiang Y, Bai Y, Wen J, Chen L. Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab. Graefes Arch Clin Exp Ophthalmol. 2016;254:31–36. https://doi.org/10.1007/s00417-015-2996-0
Huang CY, Lein R, Wang NK, Chao AN, Chen KJ, Chen TL, et al. Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2018;256:479–87. https://doi.org/10.1007/s00417-017-3878-4
Khalili S, Shifrin Y, Pan J, Belik J, Mireskandari K. The effect of a single anti-vascular endothelial growth factor injection on neonatal growth and organ development: in-vivo study. Exp Eye Res. 2018;169:54–59. https://doi.org/10.1016/j.exer.2018.01.020
Kennedy KA, Mintz-Hittner HA, for the BEAT-ROP Co-operative Group. Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity. J AAPOS. 2018;22:61–65. https://doi.org/10.1016/j.jaapos.2017.10.006
Marlow N, Stahl A, Lepore D, Fielder A, Reynolds JD, Zhu Q, et al. 2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial. Lancet Child Adolesc Health. 2021;5:698–707. https://doi.org/10.1016/S2352-4642(21)00195-4
Marlow N, Reynolds JD, Lepore D, Reynolds AR, Stahl A, Hao H, et al. Ranibizumab versus laser therapy for treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): five-year outcomes of a randomized trial. eClinicalMedicine. 2024;71:102567 https://doi.org/10.1016/j.eclinm.2024.102567
Fierson WM, American Academy of Pediatrics Section of Ophthalmology, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, American Association of Certified Orthoptists. Screening examination of premature infants for retinopathy of prematurity. Pediatrics. 2018;142:e20183061 https://doi.org/10.1542/peds.2018-3061
Author information
Authors and Affiliations
Contributions
TSR and MEH conducted the targeted literature review. REZ provided statistical analysis. TSR drafted the initial manuscript. MEH and REZ provided intellectual input and critically reviewed and revised the manuscript. All authors approved the final version of the manuscript and agree to be accountable for all aspects.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Raghuveer, T.S., Zackula, R.E. & Hartnett, M.E. Aflibercept to treat retinopathy of prematurity: need for more research. J Perinatol (2024). https://doi.org/10.1038/s41372-024-01997-1
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41372-024-01997-1